Bio-Rad Laboratories, Inc. BIOB
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 2.59B | 2.59B | 2.59B | 2.58B | 2.56B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.59B | 2.59B | 2.59B | 2.58B | 2.56B |
| Cost of Revenue | 1.24B | 1.25B | 1.25B | 1.24B | 1.21B |
| Gross Profit | 1.35B | 1.34B | 1.34B | 1.34B | 1.35B |
| SG&A Expenses | 856.60M | 845.40M | 841.20M | 837.70M | 824.90M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.35B | 2.35B | 2.35B | 2.35B | 2.32B |
| Operating Income | 246.30M | 236.70M | 241.10M | 230.60M | 240.10M |
| Income Before Tax | 1.32B | 350.40M | 222.30M | 995.50M | -842.60M |
| Income Tax Expenses | 297.30M | 128.00M | 53.50M | 235.60M | -166.70M |
| Earnings from Continuing Operations | 1.02K | 222.40 | 168.80 | 759.90 | -675.90 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.02B | 222.40M | 168.80M | 759.90M | -675.90M |
| EBIT | 246.30M | 236.70M | 241.10M | 230.60M | 240.10M |
| EBITDA | 412.00M | 405.40M | 409.30M | 396.00M | 402.20M |
| EPS Basic | 38.15 | 8.32 | 6.11 | 27.95 | -24.30 |
| Normalized Basic EPS | 6.73 | 6.58 | 6.43 | 6.51 | 6.34 |
| EPS Diluted | 37.97 | 8.25 | 6.07 | 27.91 | -24.31 |
| Normalized Diluted EPS | 6.71 | 6.58 | 6.43 | 6.51 | 6.34 |
| Average Basic Shares Outstanding | 107.46M | 107.60M | 108.08M | 109.07M | 110.09M |
| Average Diluted Shares Outstanding | 107.73M | 107.71M | 108.12M | 109.12M | 110.10M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |